only with
Biocon Ltd.
Biocon
Biocon Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Mid-cap - With a market cap of ₹690.75 Cr.
| EX-Date | Purpose |
|---|---|
| 28 04 2021 | Final Dividend & Audited Results |
| 22 07 2021 | Quarterly Results |
| 21 10 2021 | Quarterly Results |
| 20 01 2022 | Quarterly Results |
| 28 04 2022 | Audited Results & Dividend |
| 27 07 2022 | Quarterly Results |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 26 04 2023 | Inter alia, to consider the issue of Secured, Redeemable, Non-Convertible Debentures on private placement basis, investment in securities to be issued by Biocon Biologics Limited and provision of guarantees/put options, amongst other matters. |
| 23 05 2023 | Final Dividend & Audited Results & A.G.M. |
| 10 08 2023 | Quarterly Results |
| 10 11 2023 | Quarterly Results |
| 08 02 2024 | Quarterly Results |
| 16 05 2024 | Audited Results & Final Dividend |
| 30 10 2024 | Quarterly Results |
| 27 01 2025 | Inter alia, to consider and approve:- (1) Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. |
| 30 01 2025 | Quarterly Results |
| 04 04 2025 | Inter alia, to consider and approve raising funds through issuance of Commercial Papers or through any other mode |
| 23 04 2025 | Inter alia, to consider and approve the proposal for raising of funds by way of issue of equity shares or any other eligible securities, through one or more of the permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue, further public offer, etc. |
| 08 05 2025 | Final Dividend & Audited Results |
| 07 08 2025 | Quarterly Results |
| 01 10 2025 | Redemption(Part) of NCD Inter alia, it is proposed to consider early redemption of unlisted, secured, rated, redeemable, Non-Convertible Debentures (NCDs) of face value of INR 1,00,000/- each, issued and allotted by the Company on private placement basis on February 21, 2023, subject to approval of the Board of Directors of the Company proposed to be sought on October 01, 2025, and receipt of necessary approvals, on such date as may be determined by the Company. |
| 11 11 2025 | Quarterly Results |
| 06 12 2025 | Preferential Issue of shares & Inter alia, to consider and approve the proposals for: a. investment in Biocon Biologics Limited (?BBL?), an unlisted material subsidiary of the Company, by way of purchase or acquisition of securities from shareholders of BBL, for cash and/or consideration other than cash through issuance and allotment of fully paid-up equity shares of the Company on a preferential allotment basis through private placement to such shareholders, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; and b. raising of funds by way of issuance of commercial paper through private placement and/or equity shares or any other eligible securities, through one or more permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue and further public offer etc., in one or more tranchesin compliance with applicable laws and subject to requisite approvals as may be necessary, including approval of shareholders of the Company, as may be required, in this regard at an Extra-Ordinary General Meeting. |
| 12 02 2026 | Quarterly Results |
| 07 05 2026 | Final Dividend & Audited Results |
News
Biocon’s arm gets nod from Health Canada for Micafungin for injection
The approval will further strengthen the company’s integrated biosimilars and generics portfolio
Biocon reports 63% fall in Q4 consolidated net profit
The total consolidated income of the company increased by 2.59% at Rs 4,569.10 crore for Q4FY26
USFDA completes Pre-License inspection at Biocon’s biosimilars site
At the conclusion of the inspection, the USFDA issued a Form 483 with five observations
Biocon’s Bosaya, Vevzuo get NoC from Health Canada
Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer
Biocon’s arm gets USFDA’s nod for Dapagliflozin Tablets
Dapagliflozin Tablets will be manufactured at Biocon’s FDA-approved facilities, in compliance with global quality and regulatory standards
Biocon launches Bosaya, Aukelso in US
Denosumab products play a critical role in bone health, treating osteoporosis and bone complications associated with cancer
Biocon’s arm gets USFDA’s nod for ANDA of Liraglutide Injection
Biocon Pharma has received approval from USFDA for its ANDA for Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Single-Patient-Use Prefilled Pens
Biocon gets USFDA’s nod for Liraglutide Injection
According to IQVIA MAT December 2025 the total addressable market opportunity for GLP-1 in weight loss in the U.S. was $127 million
Biocon reports over five-fold jump in Q3 consolidated net profit
The consolidated total income of the company increased by 11.26% at Rs 4,290.30 crore for Q3FY26
Biocon gets VAI status for Andhra Pradesh’s API facility
This is based on an inspection conducted by the agency between November 3, 2025 and November 07, 2025
Biocon hikes stake in Biocon Biologics to 98%
The company has acquired the shares for a consideration of $200 million
Biocon’s arm gets USFDA nod for ANDA of Everolimus Tablets
Everolimus Tablets for Oral Suspension are indicated for the treatment of adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex
Biocon’s arm to introduce three new oncology biosimilars
This will enable the company to broaden the availability of critical oncology therapies through cost-effective biosimilar alternatives
Biocon signs out-licensing agreement with Ajanta Pharma
The company will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries
Biocon’s arm secures exclusive global rights for Hulio
Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure
Biocon gets EIR with VAI status for Biocon Generics Inc facility
This is based on a cGMP inspection conducted by the agency between the October 6 to October 10, 2025
Biocon launches GLP-1 peptide, Liraglutide in Netherlands
The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management
Biocon’s arm signs settlement and license agreement with Regeneron, Bayer
This agreement clears the way for Biocon Biologics to commercialize Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries worldwide
Biocon’s arm inks pact with Amgen to commercialize Denosumab biosimilars in Europe, ROW
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Biocon’s arm gets voluntary action indicated classification for Bengaluru facility
Biocon Biologics remains committed to global standards of Quality and Compliance
Biocon’s arm receives USFDA’s approval for Tofacitinib Extended-Release Tablets
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis
USFDA conducts GMP surveillance Inspection at Biocon’s API facility in Visakhapatnam
The inspection was concluded with two observations
Biocon’s arm gets Health Canada approval for Yesintek and Yesintek I.V.
Yesintek and Yesintek I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients
Biocon’s arm, Civica expand partnership to launch Insulin Glargine medicine
The collaboration is to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins
Biocon’s arm gets tentative nod for Rifaximin Tablets, 550 mg
Biocon Pharma in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from USFDA
Biocon’s arm inks settlement, license pact with Amgen
Biocon Biologics and Amgen have executed the settlement agreement to resolve the pending patent litigation
Biocon’s arm gets USFDA’s nod for Bosaya, Aukelso
In addition, the USFDA granted provisional interchangeability designation for both BOSAYA and AUKELSO
Biocon inaugurates first U.S. manufacturing facility in New Jersey
This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint
USFDA completes routine cGMP inspection at Bengaluru facility of Biocon’s arm
At the conclusion of the inspection, the USFDA issued a Form 483 with five observations
Biocon’s arm receives tentative approval from USFDA for Sitagliptin Tablets USP
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Biocon gets nod to enter into agreements with Pro-zeal Green Power Sixteen
The Board of Directors of the company at its meeting held August 07, 2025, had considered and approved the same
Biocon reports 90% fall in Q1 consolidated net profit
The total consolidated income of the company decreased by 11.95% at Rs 4,021.60 crore for Q1FY26
Biocon’s arm launches Nepexto in Australia
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe
Biocon’s arm gets USFDA’s nod for Kirsty
KIRSTY will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use
Biocon’s arm receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product
Biocon’s arm receives marketing authorisation for Vevzuo and Evfraxy in EU
Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product
Biocon’s arm expands insulin access in Malaysia
This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country
Biocon’s arm receives NOC from Health Canada for Yesafili
This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025
Biocon’s arm partners with National Cancer Society of Malaysia
This collaboration combines the company’s expertise in biosimilars with NCSM’s community outreach to enhance cancer care accessibility and affordability in Malaysia
Biocon to raise up to Rs 4,500 crore via QIP
The Fund Raising Committee of the company at its meeting held on June 16, 2025 authorised the opening of the issue
Biocon gets approval for diabetes drug Liraglutide in India
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Biocon’s arm receives MHRA, UK approval for YESINTEK, Biosimilar Ustekinumab
Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product
Biocon reports two-fold jump in Q4 consolidated net profit
The total consolidated income of the company increased by 12.31% at Rs 4,453.90 crore for Q4FY25
Biocon’s arm secures multiple market access agreements for Yesintek
The market access agreements from numerous plans represent over 100+ million lives in the United States
Biocon gets nod to raise Rs 4,500 crore
The Board of Directors at its meeting held on April 23, 2025, has inter-alia, considered and approved the same
Biocon raises Rs 600 crore through commercial papers
Maturity of the said Commercial Papers will be on September 30, 2025
Biocon’s arm inks settlement and license agreement with Regeneron
This agreement enables the company to launch ‘YESAFILI’ in the United States in the second half of calendar year 2026 or earlier in certain circumstances
Biocon’s US arm recalling 2,184 bottles of medication to treat high cholesterol
The company initiated the Class II recall on March 17, 2025
Biocon’s arm gets USFDA’s nod for Everolimus Tablets
The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products
Biocon’s arm gets USFDA’s approval for Jobevne
The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States
Biocon gets nod to raise up to Rs 600 crore through commercial papers
The Board of Directors at its meeting held on April 04, 2025, has approved the same
Biocon’s arm gets USFDA’s nod for Norepinephrine Bitartrate Injection
The approval further adds to Biocon’s portfolio of complex drug products
Biocon’s arm enters into strategic collaboration agreement with Civica
The agreement aims to expand access and affordability of Insulin Aspart in the United States
Biocon’s arm gets USFDA’s nod for Lenalidomide Capsules, Dasatinib Tablets, Rivaroxaban Tablets
Biocon Pharma received tentative approval of its ANDA for Rivaroxaban Tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths
Biocon launches GLP-1 in United Kingdom
The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda)
Biocon’s arm launches Yesintek (ustekinumab-kfce) in United States
Yesintek will be available in all the same formulations currently provided by Stelara
Biocon’s arm gets marketing authorization for YESINTEK
YESINTEK is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn’s disease
Biocon reports 89% drop in Q3 consolidated net profit
Total consolidated income of the company decreased by 14.67% at Rs 3856.20 crore for Q3FY25
Biocon gets nod to acquire stake in Biocon Biologics
Post this purchase, Biocon’s stake in BBL will be 90.2%
Biocon’s S&P Global ESG score improves to 69 for 2024
Biocon achieved an ESG Score of 76 in the Environmental Dimension, 74 in the Social Dimension, and 62 in the Governance & Economic Dimension
USFDA classifies insulins facilities of Biocon’s arm as voluntary action indicated
This relates to the cGMP inspection conducted by the agency between September 15 - 27, 2024
Biocon’s arm secures approval from PMDA for Ustekinumab BS subcutaneous injection
Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis
Biocon’s arm secures approval for Tacrolimus capsule from NMPA
The approval further adds to Biocon’s portfolio of complex drug products
Biocon, Zentiva get nod for Liraglutide in European Union
The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management
Biocon sells stake in Syngene International
Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%
Biocon gets EIR with VAI status from USFDA for Bengaluru API facility
This is based on a surveillance inspection conducted by the agency between September 23 to 27, 2024
Biocon reports 84% fall in Q2 consolidated net profit
Total consolidated income of the company increased by 0.07% at Rs 3622.90 crore for Q2FY25
USFDA classifies drug substance facility of Biocon’s arm as voluntary action indicated
This relates to the cGMP inspection conducted by the agency between February 20- 28, 2024
USFDA completes surveillance inspection at Biocon’s API facility
USFDA had conducted the said an inspection between September 23-27, 2024
USFDA completes cGMP inspection at insulins manufacturing facility of Biocon’s arm
USFDA had conducted the said an inspection between September 17-27, 2024
Biocon signs licensing and supply agreement with Biomm S.A.
Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments
Biocon’s arm transfers branded formulations business in India to Eris Lifesciences
The transaction is completed on April 2, 2024
Biocon gets approval from MHRA, UK for complex formulation Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Biocon’s arm enters into long-term commercial collaboration with Eris Lifesciences
As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly expand patient access to its world class biosimilars in India
USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm
At the conclusion of this inspection, the agency has issued Form 483s with 4 observations
Biocon gets penalty of Rs 3.04 crore over GST-related issues
The company has received an order of adjudication imposing a penalty dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore
Biocon included in S&P Global Sustainability Yearbook 2024
Biocon’s S&P Global ESG score was 63 versus 52 previously
Biocon reports consolidated net profit of Rs 753 crore in Q3
Consolidated total income of the company increased by 49.66% at Rs 4,519.20 crore for Q3FY24
Biocon’s arm enters into partnership with Sandoz
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Biocon gets tentative approval from USFDA for Dasatinib tablets
The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products
Biocon’s arm acquires biosimilars business in around 120 countries
Earlier in 2023, over 70 Emerging Markets were integrated in July, the North America business transitioned in September and the European business in November
Biocon’s associate company completes $165 million Series C financing
Thereby, Bicara will cease to be an associate company of Biocon
Biocon’s arm completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
The full transition of Viatris’ biosimilars operations to Biocon Biologics in Europe represents another significant milestone as a world-leading biosimilars company
Biocon’s arm divests BFI Non-Core Business to Eris Lifesciences
Consideration received from such sale/disposal is Rs 366 crore including working capital adjustments
Biocon’s arm enters into definitive agreement with Eris Lifesciences
The divestment of the non-core branded formulations business units in India is in line
USFDA issues official action indicated to Biocon arm’s unit in Malaysia
The OAI status may cause delay and/or withholding of pending product approvals or supplements from the facility
Biocon signs partnership agreement with Juno Pharmaceuticals
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Biocon’s arm gets European Commission’s nod for YESAFILI
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Biocon’s arm completes integration of Viatris’ biosimilars business in North America
As a result of the completion of this integration, Biocon Biologics is expected to grow its employee population to over 150 employees in North America
Biocon’s arm acquires manufacturing facility of Eywa Pharma
The facility is acquired for a total consideration of $7.7 million
CCI approves Kotak Special Situations Fund’s proposed investment in Biocon’s arm
The investment will help Biocon Biologics’ acquisition of the biosimilars business of its partner Viatris
Biocon reports 11% fall in Q1 consolidated net profit
Total consolidated income of the company increased by 58.57% at Rs 3516.10 crore for Q1FY24
USFDA completes two cGMP inspections at Malaysia Facility of Biocon Biologics’ arm
These inspections were conducted between July 10, 2023 and July 20, 2023
Biocon’s arm expands footprint in emerging markets
The company’s subsidiary has completed the integration of the acquired biosimilars business in over 70 countries
Biocon’s arm launches HULIO injection in United States
Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe
Biocon’s Bangalore API facility gets certificate of GMP compliance
The said Bangalore facility went under an EU GMP inspection in February 2023
USFDA concludes inspection of Biocon’s Oral Solid Dosage formulations manufacturing facility
The inspection has been concluded with no observations
Biocon reports 46% rise in Q4 consolidated net profit
Total consolidated income of the company increased by 58.67% at Rs 3928.80 crore for Q4FY23
Biocon’s arm gets EU GMP Certification for new mAbs facility for Bevacizumab
This approval reflects Biocon Biologics’ compliance with the highest international regulatory standards
Serum to invest additional $150 million in Biocon’s arm
BBL will have access to 100 million doses of vaccines annually together with the distribution rights to Serum’s Vaccine portfolio
Biocon’s arm wins ‘Bioprocessing Excellence in South Asia’ Award
Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey
Integrated Core Strategies (Asia) buys shares of Biocon for Rs 185 crore
Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share
Biocon redeems commercial papers of Rs 2,250 crore
The maturity date of the said commercial papers was February 22, 2023
Biocon raises Rs 1070 crore through NCDs
Date of maturity of the said NCDs will be on February 21, 2028
Biocon recalls 3,665 bottles of Posaconazole Delayed-Release Tablets in US market
The lot has been manufactured by Biocon Pharma and distributed in the US by Iselin-based Biocon Pharma Inc
Biocon offloads 10% stake in Syngene International
The shares were sold at an average price of Rs 560 apiece, taking the transaction value at Rs 2,240 crore
Biocon’s CSR arm wins IHW Gold Award
The company has received award for its Oral Cancer Screening Program by IHW Council
Biocon’s arm recognized as company with great managers at GMA 2022
Biocon Biologics is among the Top 50 Companies among 175 participating companies to feature on this prestigious list
Biocon starts clinical study of Itolizumab for Ulcerative Colitis in India
The study will cover several tertiary hospitals specialized in handling UC cases
Biocon’s arm completes acquisition of Viatris’ global biosimilars business
With this acquisition Biocon Biologics emerges as a world leading biosimilars player with eight commercialized products
Biocon raises Rs 2,250 crore through Commercial Papers
Date of maturity of said Commercial Papers will be February 22, 2023
Biocon signs semi-exclusive partnership agreement with Zentiva
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Biocon’s arm executes debt facility agreement
Debt facility agreement which is classified as a Sustainability-linked Loan amounting to $1.2 billion on November 20, 2022
Biocon reports 49% fall in Q2 consolidated net profit
Total consolidated income of the company increased by 22.56% at Rs 2384.20 crore for Q2FY23
Biocon gets nod to raise $250 million via NCDs
The Board of Directors at its meeting held on November 14, 2022, inter alia, has approved the same
Biocon’s arm featured on the prestigious Asia IP ELITE list for 2022 by lAM
Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016
Biocon named among Top 10 employers in global biotech, pharma and biopharma sector
Biocon has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees
Biocon’s arm enters into strategic out-licensing agreement with Yoshindo
Under the terms of this deal, Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
EDQM conducts GMP inspection at Biocon’s Bangalore unit
There were no critical deficiencies and one deficiency cited under the category ‘Major’
Biocon divests 5.4% stake in Syngene International
The company has sold a total of 21,789,164 shares, at an average price of Rs 560.04 apiece, in Syngene International
USFDA issues three observations to Biocon’s Telangana manufacturing plant
Three observations were cited at the end of the inspection, which the company will be addressing within the stipulated time
Biocon’s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru
The facility, spread across 340,000-square feet, will enhance capabilities manifold to manufacture drug substance of mAbs portfolio